NervGen Pharma Corp. (NGEN.V)
| Previous Close | 2.7000 |
| Open | 2.7500 |
| Bid | 2.7400 x 0 |
| Ask | 2.7500 x 0 |
| Day's Range | 2.7500 - 2.7900 |
| 52 Week Range | 1.2600 - 3.3300 |
| Volume | |
| Avg. Volume | 78,429 |
| Market Cap | 126.879M |
| Beta (5Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3540 |
| Earnings Date | Nov. 18, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.53 |
- Business Wire
NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabilitation
VANCOUVER, British Columbia, January 10, 2022--NervGen Pharma announces it has entered into a Memorandum of Understanding with Shirley Ryan AbilityLab.
- Newsfile
NervGen Pharma Applauds President Biden Signing Defense Bill
Department of Defense now able to Move Forward on Brain Plasticity Research Cincinnati, Ohio--(Newsfile Corp. - January 4, 2022) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF) through its subsidiary, NervGen US Inc., ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, applauds President Biden for signing the Fiscal Year 2022 National Defense Authorization Act (FY22 NDAA) into law on December 27th, 2021. The Se
- Newsfile
NervGen Pharma Receives Ethics Board Approval for Multiple Ascending Dose Portion of NVG-291 Phase 1 Trial
Phase 1 program supports plan to start clinical trials in H2 2022 for NervGen's NVG-291 in spinal cord injury, multiple sclerosis and Alzheimer's disease indications Screening of healthy volunteers has already started for the trial's multiple ascending dose (MAD) portionIn preclinical studies, NVG-291 has been shown to promote repair of nervous system damageVancouver, British Columbia--(Newsfile Corp. - December 22, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Comp
